U.S. markets closed
  • S&P 500

    3,826.31
    +52.45 (+1.39%)
     
  • Dow 30

    30,687.48
    +475.57 (+1.57%)
     
  • Nasdaq

    13,612.78
    +209.38 (+1.56%)
     
  • Russell 2000

    2,151.19
    +25.02 (+1.18%)
     
  • Crude Oil

    54.86
    +1.31 (+2.45%)
     
  • Gold

    1,836.60
    -27.30 (-1.46%)
     
  • Silver

    26.58
    -2.84 (-9.65%)
     
  • EUR/USD

    1.2044
    -0.0023 (-0.19%)
     
  • 10-Yr Bond

    1.1050
    +0.0280 (+2.60%)
     
  • GBP/USD

    1.3662
    -0.0005 (-0.04%)
     
  • USD/JPY

    105.0330
    +0.0940 (+0.09%)
     
  • BTC-USD

    35,700.14
    +1,755.91 (+5.17%)
     
  • CMC Crypto 200

    726.51
    +41.73 (+6.09%)
     
  • FTSE 100

    6,516.65
    +50.23 (+0.78%)
     
  • Nikkei 225

    28,362.17
    +271.12 (+0.97%)
     

ROCE Insights For Inovio Pharmaceuticals

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
Updated ·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

During Q3, Inovio Pharmaceuticals's (NASDAQ:INO) reported sales totaled $236.18 million. Despite a 25.02% in earnings, the company posted a loss of $36.33 million. In Q2, Inovio Pharmaceuticals brought in $267.19 thousand in sales but lost $29.06 million in earnings.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Inovio Pharmaceuticals posted an ROCE of -0.11%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on INO

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Inovio Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q3 Earnings Recap

Inovio Pharmaceuticals reported Q3 earnings per share at $-0.26/share, which did not meet analyst predictions of $-0.19/share.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Originally published